| Boceprevir for untreated chronic HCV genotype 1 infection F Poordad, J McCone Jr, BR Bacon, S Bruno, MP Manns, MS Sulkowski, ... New England Journal of Medicine 364 (13), 1195-1206, 2011 | 3375 | 2011 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Jounal of Medicine 370 (16), 1483-1493, 2014 | 1714 | 2014 |
| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1558 | 2014 |
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases MG Ghany, DR Nelson, DB Strader, DL Thomas, LB Seeff Hepatology 54 (4), 1433-1444, 2011 | 1518 | 2011 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1423 | 2013 |
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ... New England Journal of Medicine 360 (18), 1827-1838, 2009 | 1417 | 2009 |
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. BB 22. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D ... New England Journal of medicine 370 (17), 1594-603, 2014 | 1133 | 2014 |
| Response-guided telaprevir combination treatment for hepatitis C virus infection KE Sherman, SL Flamm, NH Afdhal, DR Nelson, MS Sulkowski, ... New England Journal of Medicine 365 (11), 1014-1024, 2011 | 1047 | 2011 |
| All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study DR Nelson, JN Cooper, JP Lalezari, E Lawitz, PJ Pockros, N Gitlin, ... Hepatology 61 (4), 1127-1135, 2015 | 895 | 2015 |
| Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER … Kncet | 796 | 2015 |
| Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin S Zeuzem, IM Jacobson, T Baykal, RT Marinho, F Poordad, M Bourlière, ... New England Journal of Medicine 370 (17), 1604-1614, 2014 | 785 | 2014 |
| An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection R Cabrera, Z Tu, Y Xu, RJ Firpi, HR Rosen, C Liu, DR Nelson Hepatology 40 (5), 1062-1071, 2004 | 772 | 2004 |
| Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 ML Shiffman, F Suter, BR Bacon, D Nelson, H Harley, R Solá, SD Shafran, ... New England Journal of Medicine 357 (2), 124-134, 2007 | 766 | 2007 |
| Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: role of hepatitis C and B infections MS Sulkowski, DL Thomas, SH Mehta, RE Chaisson, RD Moore Hepatology 35 (1), 182-189, 2002 | 749 | 2002 |
| Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review O Falade-Nwulia, C Suarez-Cuervo, DR Nelson, MW Fried, JB Segal, ... Annals of internal medicine 166 (9), 637-648, 2017 | 721 | 2017 |
| Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection SA Villano, D Vlahov, KE Nelson, S Cohn, DL Thomas Hepatology 29 (3), 908-914, 1999 | 667 | 1999 |
| Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders DR Nelson, GY Lauwers, JYN Lau, GL Davis Gastroenterology 118 (4), 655-660, 2000 | 478 | 2000 |
| Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment E Gane, E Lawitz, D Pugatch, G Papatheodoridis, N Bräu, A Brown, S Pol, ... New England Journal of Medicine 377 (15), 1448-1455, 2017 | 441 | 2017 |
| Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised … E Lawitz, JP Lalezari, T Hassanein, KV Kowdley, FF Poordad, AM Sheikh, ... The Lancet infectious diseases 13 (5), 401-408, 2013 | 434 | 2013 |
| Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label … X Forns, SS Lee, J Valdes, S Lens, R Ghalib, H Aguilar, F Felizarta, ... The Lancet infectious diseases 17 (10), 1062-1068, 2017 | 414 | 2017 |
Mark S. Sulkowski, MDProfessor of Medicine; Johns Hopkins University School of MedicineVerified email at jhmi.edu
